Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Sells $29,595.96 in Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Marc Duey sold 6,462 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the completion of the sale, the director now directly owns 233,651 shares in the company, valued at approximately $1,070,121.58. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Marc Duey also recently made the following trade(s):

• On Wednesday, October 16th, Marc Duey acquired 30,000 shares of Aprea Therapeutics stock. The stock was acquired at an average price of $4.39 per share, for a total transaction of $131,700.00.
• On Monday, October 14th, Marc Duey acquired 190 shares of Aprea Therapeutics stock. The stock was acquired at an average price of $2.58 per share, for a total transaction of $490.20.

Aprea Therapeutics Stock Up 4.6 %

NASDAQ:APRE opened at $4.08 on Friday. Aprea Therapeutics, Inc. has a 52 week low of $2.15 and a 52 week high of $8.85. The company’s 50 day moving average price is $3.27 and its 200-day moving average price is $4.10. The stock has a market cap of $22.15 million, a price-to-earnings ratio of -1.23 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.05. The business had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $0.10 million. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. As a group, sell-side analysts anticipate that Aprea Therapeutics, Inc. will post -2.74 earnings per share for the current year.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned 0.20% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on APRE. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research report on Thursday. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.